{"id":3408,"date":"2026-09-17T10:40:43","date_gmt":"2026-09-17T10:40:43","guid":{"rendered":"https:\/\/alipanc.org\/pantheia-seom-validates-siri-as-a-prognostic-marker-in-metastatic-pancreatic-cancer\/"},"modified":"2026-09-17T10:40:43","modified_gmt":"2026-09-17T10:40:43","slug":"pantheia-seom-validates-siri-as-a-prognostic-marker-in-metastatic-pancreatic-cancer","status":"publish","type":"post","link":"https:\/\/alipanc.org\/en\/pantheia-seom-validates-siri-as-a-prognostic-marker-in-metastatic-pancreatic-cancer\/","title":{"rendered":"PANTHEIA-SEOM Validates SIRI as a Prognostic Marker in Metastatic Pancreatic Cancer"},"content":{"rendered":"<p>The multicenter study included 672 patients treated with first-line chemotherapy. A low SIRI score (\u22642.3) was associated with longer overall survival (14.0 vs. 9.2 months). It was also associated with longer progression-free survival (5.9 vs. 3.9 months) and a higher tumor response rate (37% vs. 25%). In addition to the classic cutoff point, the SIRI was analyzed as a continuous variable. This analysis revealed a nonlinear relationship between increasing SIRI and a worse prognosis. A high SIRI score was also associated with a higher hepatic tumor burden and cachexia.<br \/>\nAn open-access web calculator allows users to explore this continuous prognostic gradient on an individualized basis: <a href=\"https:\/\/urldefense.com\/v3\/__https:\/pantheia-siri.shinyapps.io\/calc\/__;!!D9dNQwwGXtA!VFeRCnktmW5oIffYU8EeXC8ap70MfwMxN4GXWaUzpykPbTYeX3izWboUHzVQzEV5I9FY0X5BC54qEYRjcL_cUkAOhP4$\">https:\/\/pantheia-siri.shinyapps.io\/calc\/<\/a>.     <\/p>\n<p>The collaborative study was led by Vilma Pacheco-Barcia and has been published in the journals *Pancreatology* and *Clinical Translational Oncology*.<\/p>\n<p>&nbsp;<\/p>\n<p><strong>PMID <\/strong><strong>42601286, 42690293<\/strong><\/p>\n<p>doi: 10.1016\/j.pan.2026.08.008<\/p>\n<p>doi: 10.1007\/s12094-026-04554-8<\/p>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>The multicenter study included 672 patients treated with first-line chemotherapy. A low SIRI score (\u22642.3) was associated with longer overall survival (14.0 vs. 9.2 months). It was also associated with longer progression-free survival (5.9 vs. 3.9 months) and a higher tumor response rate (37% vs. 25%). In addition to the classic cutoff point, the SIRI [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","inline_featured_image":false,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-3408","post","type-post","status-publish","format-standard","hentry","category-sin-categorizar"],"_links":{"self":[{"href":"https:\/\/alipanc.org\/en\/wp-json\/wp\/v2\/posts\/3408","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alipanc.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alipanc.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alipanc.org\/en\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/alipanc.org\/en\/wp-json\/wp\/v2\/comments?post=3408"}],"version-history":[{"count":0,"href":"https:\/\/alipanc.org\/en\/wp-json\/wp\/v2\/posts\/3408\/revisions"}],"wp:attachment":[{"href":"https:\/\/alipanc.org\/en\/wp-json\/wp\/v2\/media?parent=3408"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alipanc.org\/en\/wp-json\/wp\/v2\/categories?post=3408"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alipanc.org\/en\/wp-json\/wp\/v2\/tags?post=3408"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}